Similarities and differences between European and United States guidelines for the management of dyslipidaemias

Kardiologia Polska

Volumn 73, Issue 7, 2015, Pages 471-477

  Reiner, Željko ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DRUG HYPERSENSITIVITY; DYSLIPIDEMIA; EUROPEAN; HUMAN; META ANALYSIS (TOPIC); MONOTHERAPY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; UNITED STATES; ADULT; AGED; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; DIET THERAPY; DYSLIPIDEMIAS; EUROPE; FEMALE; MALE; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 84937157488     PISSN: 00229032     EISSN: 18974279     Source Type: Journal    
DOI: 10.5603/KP.2015.0121     Document Type: Review

References (56)

1. Reiner Ž, Catapano AL, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J, 2011; 32: 1769-1818.
2. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J, 2012; 33: 1635-1701.
3. Stone NJ, Robinson JG, Lichtenstein AH et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2014; 129: S1-S45.
4. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet, 2013; 382: 1762-1765.
5. Reiner Ž. Guidelines, position papers and critical reviews: differences and similarities. Eur J Prev Cardiol, 2013; 20: 3-5.
6. De Backer G, Catapano AL, Chapman J et al. Guidelines on CVD prevention: confusing or complementary? Atherosclerosis, 2013; 226: 299-300.
7. Reiner Ž. A comparison of European and US guidelines for familial hypercholesterolemia. Curr Opin Lipidol 2015; 26: 215-220.
8. Chapman MJ, Ginsberg HN, Amarenco P et al. for the European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for menagement. Eur Heart J, 2011; 332: 1345-1361.
9. Nordestgaard BG, Chapman J, Ray K et al.; for the European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J, 2010; 23: 2844-2853.
10. Conroy R, Pyorala K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J, 2003; 24: 987-1003.
11. D'Agostino RB Sr, Vasan RS, Pencina MJ et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation, 2008; 117: 743-753.
12. Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk. A review for clinicians. J Am Coll Cardiol, 2009; 54: 1209-1227.
13. Cooney MT, Dudina A, d'Agostino R et al. Cardiovascular risk estimation systems in primary prevention. Do they differ? Do they make a difference? Can we see the future? Circulation, 2010; 122: 300-310.
14. Reiner Ž. New ESC/EAS Guidelines for the management of dyslipidaemias: any controversies behind the consensus? Eur J Cardiovasc Prev Rehabil, 2011; 18:724-727.
15. Ades PA. A controversial step forward: a commentary on the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Coron Artery Dis, 2014; 25: 360-363.
16. Maddox TM, Borden WB, Tang F et al. Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry. J Am Coll Cardiol, 2014; 64: 2183-2192.
17. DeFilippis AP, Young R, Carrubba CJ et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med, 2015; 162: 266-275.
18. Ridker PM, Cook NR. Comparing cardiovascular risk prediction scores. Ann Intern Med, 2015; 162: 313-315.
19. Tournadre A, Tatar Z, Pereira B et al. Application of the European Society of Cardiology, Adult Treatment Panel III and American College of Cardiology/American Heart Association guidelines for cardiovascular risk management in a French cohort of rheumatoid arthritis. Int J Cardiol, 2015; 183: 149-154.
20. Pencina MJ, Navar-Boggan AM, D'Agostino RB Sr et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med, 2014; 370: 1422-1431.
21. Reiner Ž. Primary prevention of cardiovascular disease with statins in the elderly. Curr Atheroscler Rep, 2014; 16: 420-426.
22. Šimić I, Reiner Ž. Adverse effects of statins: myths and reality. Curr Pharm Des, 2015; 21: 1220-1226.
23. Reiner Ž. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol, 2013; 10: 453-464.
24. Rajpathak SN, Kumbhani DJ, Crandall J et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care, 2009; 32: 1924-1929.
25. Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, 2010; 375: 735-742.
26. Culver AL, Ockene IS, Balasubramanian R et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med, 2012; 172: 144-152.
27. Preiss D, Seshasai SR, Welsh P et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA, 2011; 305: 2556-2564.
28. Cederberg H, Stančáková A, Yaluri N et al. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia, 2015; 58: 1109-1117.
29. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults : Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 2001; 285: 2486-2497.
30. Graham I, Cooney MT, Bradley D et al. Dyslipidemias in the prevention of cardiovascular disease: risks and causality. Curr Cardiol Rep, 2012; 14: 709-720.
31. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J, 2007; 28: 2375-2414.
32. Baigent C, Blackwell L, Emberson J et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-1681.
33. Ray KK, Kastelein JJ, Boekholdt SM et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J, 2014; 35: 960-968.
34. Eckel RH. Approach to the patient who is intolerant of statin therapy. J Clin Endocrinol Metab, 2010; 95: 2015-2022.
35. Reiner Ž. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis, 2014; 24: 1057-1066.
36. Kataoka Y, John JS, Wolski K et al. Atheroma progression in hyporesponders to statin therapy. Arterioscler Thromb Vasc Biol, 2015; 35: 990-995.
37. Wei L, MacDonald TM, Watson AD et al. Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study. Pharmacoepidemiol Drug Saf, 2007; 16: 385-392.
38. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA, 2002; 288: 462-467.
39. Mann DM, Woodward M, Muntner P et al. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother, 2010; 44: 1410-1421.
40. Reiner Ž, Tedeschi-Reiner E. Prevalence and types of persistent dyslipidemia in patients treated with statins. Croat Med J, 2013; 54: 339-345.
41. Chowdhury R, Khan H, Heydon E et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J, 2013; 34: 2940-2908.
42. Reiner Ž. Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol, 2010; 24: 19-28.
43. Reiner Ž. Combination therapy with prescription omega-3acid ethyl esters and statin improves non-HDL-C more effectively than statin alone. Clin Lipidol, 2010; 5: 325-328.
44. Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med, 2015; 372: 2387-2397.
45. Barkas F, Milionis H, Kostapanos MS et al. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. Curr Med Res Opin, 2015; 31: 221-228.
46. Fruchart J-C, Sacks F, Hermans MP et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidemic patients. A position paper by the Residual Risk Reduction Initiative (R3 I). Diabetes Vasc Dis Res, 2008; 4: 319-335.
47. Reiner Ž. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr Metab Cardiovasc Dis, 2013; 23: 799-807.
48. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J, 2013; 34: 1279-1291.
49. Ministry of Health, Labour and Welfare (MHLW). Advisory committee on applications for approval of drugs (in Japanese). Available at: http://www.mhlw.go.jp/shingi/2004/10/txt/s1018-4.txt.
50. Kim NH, So MS, Kang JG et al. Application of new guidelines for the primary prevention of atherosclerotic cardiovascular disease in a Korean population. J Atheroscler Thromb, 2015; 22: 293-303.
51. Reiner Ž, Sonicki Z, Tedeschi-Reiner E. Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. Atherosclerosis, 2010; 213: 598-603.
52. Reiner Ž, Sonicki Z, Tedeschi-Reiner E. The perception and knowledge of cardiovascular risk factors among medical students. Croat Med J, 2012; 53: 278-284.
53. Reiner Z, Sonicki Z, Tedeschi-Reiner E. Public perceptions of cardiovascular risk factors in Croatia: The PERCRO survey. Prev Med, 2010; 51: 494-496.
54. Zannad F, Dallongeville J, Macfadyen RJ et al. Prevention of cardiovascular disease guided by total risk estimations: challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy. Eur J Prev Cardiol, 2012; 19: 1454-1464.
55. Reiner Ž. How to improve cardiovascular diseases prevention in Europe? Nutr Metab Cardiovasc Dis, 2009; 19: 451-454.
56. Reiner Ž, De Bacquer D, Kotseva K et al.; EUROASPIRE III Study Group.Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: Findings from the EUROASPIRE III survey. Atherosclerosis, 2013; 231: 300-307.